Letters
Acknowledgment. This work was supported through
Journal of Medicinal Chemistry, 2004, Vol. 47, No. 23 5615
(15) McCague, R.; LeClercq, G.; Jordan, V. C. Nonisomerizable
Analogues of (Z)- and (E)-4-Hydroxytamoxifen. Synthesis and
Endocrinological Properties of Substituted Diphenylbenzocyclo-
heptenes. J. Med. Chem. 1988, 31, 1285-1290.
(16) McCague, R. An analogue of the antioestrogen tamoxifen of
sufficient rigidity to exist as distinct enantiomers: synthesis and
conformational dynamics studies. Tetrahedron Asymm. 1990, 11,
97-110.
(17) Henke, B. R.; Consler, T. G.; Go, N.; Hale, R. L.; Hohman, D.
R.; Jones, S. A.; Lu, A. T.; Moore, L. B.; Moore, J. T.; Orband-
Miller, L. A.; Robinett, R. G.; Shearin, J.; Spearing, P. K.;
Stewart, E. L.; Turnbull, P. S.; Weaver, S. L.; Williams, S. P.;
Wisely, G. B.; Lambert, M. H. A new series of estrogen receptor
modulators that display selectivity for estrogen receptor beta.
J. Med. Chem. 2002, 45, 5492-5505.
(18) Meegan, M. J.; Hughes, R. B.; Lloyd, D. G.; Williams, D. C.;
Zisterer, D. M. Ethyl side-chain modifications in novel flexible
antiestrogens - design, synthesis and bilogical efficacy in assay
against the MCF-7 breast tumor cell line. Anti-Cancer Drug Des.
2001, 16, 57-69.
funding from BioResearch Ireland (now the Enterprise
Ireland Biotechnology Directorate) and the Trinity
College IITAC research initiative, part of the Irish
Higher Education Authority’s program for research in
third level institutes (PRTLI), with additional support
for our computational facilities gained through equip-
ment funding from the Wellcome Trust. D.G.L. and
M.J.M. are most grateful to Enterprise Ireland’s Inter-
national Collaboration Scheme for facilitating an inter-
institutional research visit during the course of this
program.
Supporting Information Available: Experimental de-
tails, analytical and spectral data for final compounds, and
biochemical and computational procedures employed. This
material is available free of charge via the Internet at
(19) Meegan, M. J.; Hughes, R. B.; Lloyd, D. G.; Williams, D. C.;
Zisterer, D. M. Flexible estrogen receptor modulators - design,
synthesis and antagonistic effects in human MCF-7 breast
cancer cells. J. Med. Chem. 2001, 44, 1072-1084.
References
(20) Singh, M. M. Centchroman, a selective estrogen receptor modu-
lator, as a contraceptive and for the management of hormone
related disorders. Med. Res. Rev. 2001, 21, 302-347.
(21) Catherino, W. H.; Jordan, V. C. Increasing the number of tandem
estrogen response elements increases the estrogenic activity of
a tamoxifen analogue. Cancer Lett. 1995, 92, 39-47.
(1) Katzenellenbogen, B. S. Estrogen receptors: bioactivities and
interactions with cell signaling pathways. Biol. Reprod. 1996,
54, 287-293.
(2) Beato, M.; Sanchez-Pacheco, A. Interaction of steroid hormone
receptors with the transcription initiation complex. Endocr. Rev.
1996, 17, 587-609.
(22) Blizzard, T. A.; Morgan, J. D.; Mosley, R. T.; Birzin, E. T.; Frisch,
(3) Lloyd, D. G.; Meegan, M. J. Recent advances in estrogen receptor
antagonists. IDrugs 2000, 3, 343-353.
K.; Rohrer, S. P.; Hammond, M. L. 2-Phenylspiroindenes:
A
Novel Class of Estrogen Receptor Modulators (SERMs). Bioorg.
Med. Chem. Lett. 2003, 13, 479-483.
(4) Meegan, M. J.; Lloyd, D. G. Advances in the Science of Estrogen
Receptor Modulators. Curr. Med. Chem. 2003, 10, 181-210.
(5) Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P.
J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen
receptor/coactivator recognition and the antagonism of this
interaction by tamoxifen. Cell 1998, 95, 927.
(23) Tandon, V. K.; Khanna, J. M.; Arand, N.; Chandra, A. Phen-
ethylamine in a rigid framework: synthesis, stereochemistry and
reactions of cis and trans-4-amino-2,3,4,5-tetrahydro-1-benzox-
epin-5-ols and their derivatives. Tetrahedron 1990, 46, 2871-
2882.
(6) Lerner, L. J.; Jordan, V. C. Development of antiestrogens and
their use in breast cancer: Eighth Cain Memorial Award
Lecture. Cancer Res. 1990, 50, 4177-4189.
(7) Shani, J.; Gazit, A.; Licshitz, T.; Biran, S. Synthesis and receptor
binding affinity of fluorotamoxifen, a possible estrogen-receptor
imaging agent. J. Med. Chem. 1985, 28, 1504-1511.
(8) Itami, K.; Kamei, T.; Yoshida, J. Diversity-oriented synthesis
of tamoxifen-type tetrasubstituted olefins. J. Am. Chem. Soc.
2003, 125, 14670-14671.
(9) Lloyd, D. G.; Buenemann, C. L.; Todorov, N. P.; Manallack, D.
T.; Dean, P. M. Scaffold hopping in de novo design - ligand
generation in the absence of receptor information. J. Med. Chem.
2004, 47, 493-496.
(10) Schmidt, J. M.; Mercure, J.; Tremblay, G. B.; Page, M.; Kalbakji,
A.; Feher, M.; Dunn-Dufault, R.; Peter, M. G.; Redden, P. R. De
novo design, synthesis, and evaluation of novel nonsteroidal
phenanthrene ligands for the estrogen receptor. J. Med. Chem.
2003, 46, 1408-1418
(11) Wolf, D. M.; Langan-Fahey, S. M.; Parker, C. J.; McCague, R.;
Jordan, V. C. Investigation of the mechanism of tamoxifen-
stimulated breast-tumor growth with nonisomerizable analogues
of tamoxifen and metabolites. J. Natl. Cancer Inst. 1993, 85,
806-812.
(12) Leichtl, S.; von Angerer, E. 2-Phenylbenzo[b]thiophene-based
antiestrogens with mammary tumour inhibiting activity. Arch.
Pharm. 1998, 331, 283-289.
(13) Teo, C. C.; Kon, O. L.; Sim, K. Y.; Ng, S. C. Synthesis of 2-(para-
chlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands
for antiestrogen-binding sites - effects on cell proliferation and
cholesterol synthesis. J. Med. Chem. 1992, 35, 1330-1339.
(14) McCague, R.; Kuroda, R.; Leclercq, G.; Stoessel, S. Synthesis
and Estrogen Receptor Binding of 6,7-Dihydro-8-phenyl-9-[4-[2-
(dimethylamino)ethoxy]phenyl]-5H-benzocycloheptene, a Non-
isomerisable Analogue of Tamoxifen. X-ray Crystallographic
Studies. J. Med. Chem. 1986, 29, 2053-2059.
(24) Feiser, L. F.; Feiser, M. Reagents for Organic Chemistry; Wiley
& Sons: London, 1987; Vol. 1, pp 967-970.
(25) Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling
reactions of organoboron compounds. Chem. Rev. 1995, 95,
2457-2483.
(26) Brown, A. G.; Crimmin, M. J.; Edwards, P. D. Application of
the Suzuki biphenyl synthesis to the natural products bipheno-
mycin and vancomycin, J. Chem. Soc., Perkin Trans. 1 1992,
123-130.
(27) Morgan, J.; Hambley, T. W.; Pinley, J. T. Mechanism of arylation
of nucleophiles by aryllead triacetates. Part 3. Concerning their
reaction with phenols and X-ray molecular structure of p-
methoxyphenyllead triacetate. J. Chem. Soc., Perkin Trans. 1
1996, 2173-2176.
(28) Cundy, D. J.; Forsyth, S. A. Cupric acetate mediated N-arylation
by arylboronic acids: a preliminary investigation into the scope
of application. Tetrahedron Lett. 1998, 39, 7979-7982.
(29) Yang, D. J.; Wallace, S.; Tansey, W.; Wright, K. C.; Wuang, L.
R.; Tilbury, R. S.; Diego, I.; Lim, J. L.; Emran, A. M.; Kim, E. E.
Synthesis and in vitro receptor-binding studies of fluorotamox-
ifen analogues. Pharm. Res. 1991, 8, 174-177.
(30) Fishman, J. H. Stabilization of estradiol-receptor complexes by
elimination of cytosolic factors. Biochem. Biophys. Res. Commun.
1983, 110, 713-718.
(31) Sobolev, V.; Wade, R. C.; Vriend, G.; Edelman, M. Molecular
docking using surface complementarity. Proteins 1996, 25, 120-
129.
(32) Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible
docking method using an incremental construction algorithm J.
Mol. Biol. 1996, 261, 470-489.
(33) Discover module in InsightII, Accelrys Inc., 2000.
JM0495834